March 30 Update: New Information on Diagnostic Testing for SARS-CoV-2
March 31, 2020
Thank you for your interest in development of diagnostics for SARS-CoV-2. On March 30, 2020, the FDA updated the frequently asked questions on diagnostic testing to include new and updated information on:
- When FDA authorizes a SARS-CoV-2 test for use at the point of care, does that mean it is CLIA waived?
- I am developing a COVID-19 assay that is a modification of a previously EUA authorized COVID-19 assay. Do I need to start from scratch with my validation or can I validate my test with a bridging study?
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
